sj-docx-1-tam-10.1177_17588359211045845 ��� Supplemental material for Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

Autor:	Socinski, Mark A., Waller, Cornelius F., Idris, Tazeen, Bondarenko, Igor, Luft, Alexander, Beckmann, Katrin, Vishweswaramurthy, Ashwini, Loganathan, Subramanian, Donnelly, Charles, Hummel, Matthew A., Shapiro, Roxann, Woods, Melody, Rao, Anita, Nayak, Vivek G, Ranganna, Gopinath, Barve, Abhijit
Rok vydání:	2021
Předmět:	110203 Respiratory Diseases FOS: Clinical medicine 111702 Aged Health Care FOS: Health sciences 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified 111299 Oncology and Carcinogenesis not elsewhere classified
ISSN:	1758-8359
DOI:	10.25384/sage.17049090
Popis:	Supplemental material, sj-docx-1-tam-10.1177_17588359211045845 for Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer by Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna and Abhijit Barve in Therapeutic Advances in Medical Oncology
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d73e492154af54f122107e7840bb7ca9 Zobrazit plný text záznamu